NWBO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NWBO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Northwest Biotherapeutics's EBITDA for the three months ended in Dec. 2023 was $-17.26 Mil. Northwest Biotherapeutics's Revenue for the three months ended in Dec. 2023 was $0.45 Mil. Therefore, Northwest Biotherapeutics's EBITDA margin for the quarter that ended in Dec. 2023 was -3,877.75%.
The historical data trend for Northwest Biotherapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Northwest Biotherapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EBITDA Margin % | Get a 7-Day Free Trial | -740.12 | -40,344.85 | 18,380.40 | -5,791.09 | -2,879.14 |
Northwest Biotherapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EBITDA Margin % | Get a 7-Day Free Trial | -4,471.52 | -1,048.07 | -6,330.85 | -4,044.58 | -3,877.75 |
For the Biotechnology subindustry, Northwest Biotherapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Northwest Biotherapeutics's EBITDA Margin % falls into.
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Northwest Biotherapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
Northwest Biotherapeutics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Northwest Biotherapeutics (OTCPK:NWBO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Thank you for viewing the detailed overview of Northwest Biotherapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Navid Malik | director | 1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET |
Marnix L Bosch | officer: Chief Technical Officer | 22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021 |
Alton L Boynton | director, officer: Chief Scientific Officer | 22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021 |
Leslie J. Goldman | officer: See Remarks | C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814 |
Linda F Powers | director, 10 percent owner, officer: President and CEO | 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814 |
Jerry J Jasinowski | director | C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888 |
Jean M. Davis | officer: See Remarks | 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814 |
Susan B Bayh | director | WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
Black Cofer | director | 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814 |
Woodford Investment Management Llp | 10 percent owner | 27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX |
Cf Woodford Equity Income Fund | 10 percent owner | C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN |
Cognate Bioservices, Inc. | 10 percent owner | 7513 CONNELLEY DRIVE, HANOVER MD 21076 |
Robert A Farmer | director | 10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154 |
Toucan General Ii, Llc | 10 percent owner | 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814 |
Hemphill Robert F Jr. | 10 percent owner | 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814 |
From GuruFocus
By PRNewswire PRNewswire • 05-20-2022
By PRNewswire • 11-22-2023
By PRNewswire PRNewswire • 11-29-2021
By PRNewswire PRNewswire • 07-06-2022
By PRNewswire PRNewswire • 01-06-2023
By PRNewswire • 09-12-2023
By PRNewswire • 10-13-2023
By PRNewswire PRNewswire • 12-21-2021
By PRNewswire PRNewswire • 10-28-2021
By PRNewswire PRNewswire • 03-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.